Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
7(87.5%)
Phase 1
1(12.5%)
8Total
Phase 2(7)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT07088159Unknown

Intermediate-size Patient Population Expanded Access Protocol

Role: lead

NCT07325591Phase 2Not Yet Recruiting

Efficacy and Safety of Tazbentetol in ALS Participants

Role: lead

NCT07439510Phase 2Not Yet Recruiting

A Study to Investigate the Effects and Safety of SPG601 for the Treatment of Fragile X Syndrome in Male Participants

Role: lead

NCT06442462Phase 2Active Not Recruiting

Study of SPG302 in Adults With Schizophrenia

Role: lead

NCT06833281Phase 2Terminated

Extension Study of Participants From SPG302-ALZ-101

Role: lead

NCT06903286Phase 2Terminated

Extension Study of Participants From SPG302-ALS-001

Role: lead

NCT06427668Phase 2Active Not Recruiting

Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

Role: lead

NCT05882695Phase 1Completed

Study of SPG302 in Healthy Volunteers and ALS Participants

Role: lead

NCT06413537Phase 2Completed

Study of SPG601 in Adult Men With Fragile X Syndrome

Role: lead

All 9 trials loaded